Solid Tumor

• Bladder Cancer

  Immunotherapy: PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, avelumab) have reshaped the treatment landscape for advanced urothelial carcinoma. Antibody-Drug Conjugates (ADCs): Enfortumab vedotin (Padcev®) and sacituz...

• Breast Cancer

  Breast cancer is the most common cancer among women globally. It is a heterogeneous disease with several subtypes, each requiring a tailored approach.

• Colon Cancer

  Colorectal cancer is the second leading cause of cancer death in the U.S. Most cases arise from adenomatous polyps and develop slowly over years, making screening vital for early detection.

• Lung Cancer

  Lung cancer remains the leading cause of cancer-related death worldwide and is broadly categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 85% of cases and includes a...

• Melanoma

  Melanoma is a malignant tumor of melanocytes, most often caused by UV exposure. While once lethal in its metastatic form, it has become a showcase for breakthroughs in immunotherapy and targeted therapy.

• Prostate Cancer

  Traditionally hormone-driven, prostate cancer therapy has advanced beyond androgen deprivation.

• Renal Cell Carcinoma (RCC)

  Combination Immunotherapy: Dual checkpoint blockade (nivolumab + ipilimumab) provides durable remission in advanced disease. VEGF TKIs: Cabozantinib, lenvatinib, and axitinib remain central to controlling angiogenesis. N...